Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences will participate in the BIO International Convention 2026 (June 22-25) in San Diego. The company will showcase its differentiated CNS clinical candidates and explore partnering strategies for its late-stage assets, including 62 pre-scheduled meetings.
Jun 22 2026 10:23:37
Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences announced positive topline results from its Phase-2b clinical trial of Ropanicant for Major Depressive Disorder, demonstrating clinically meaningful improvement. A global Phase-3 registrational study for the drug is now being planned.
Jun 17 2026 12:34:57
Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences successfully completed its Phase-1 clinical study of SUVN-I6107, a Muscarinic M1 PAM, demonstrating favorable safety and CNS activity. The drug will now advance to Phase-2 clinical development for Central Nervous System disorders. This marks a key pipeline milestone.
Jun 16 2026 09:25:54
Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences will present three posters on Samelisant (SUVN-G3031) at the SLEEP-2026 Annual Meeting. This includes positive Phase 2 efficacy data for excessive daytime sleepiness and details of the global Phase 3 AWAKE Narcolepsy Study.
Jun 12 2026 11:23:32
Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences' global Phase 3 study of Masupirdine (SUVN-502) for Alzheimer's disease agitation received a positive DSMB safety review and interim analysis. The study will continue as planned without modifications, with 88% enrollment completed and top-line results expected in Q2 2027.
Jun 04 2026 10:54:11
Read More